6 myths about GLP-1 Agonists that need to die
In a couple of months Ozempic/Wegovy will be off-patent.
Many patients in India will be able to afford them
Many doctors would be able to prescribe them to the “right candidates”
With more widespread availability there will be more noise about GLP-1s (there already is).
I see a lot of these on social media.
Here are 6 myths about GLP-1 Agonists that need to die
Myth 1: GLP-1s Are a Magic Bullet
The idea that semaglutide or tirzepatide will melt fat while you continue eating pizza on the couch misunderstands how these drugs work.
The STEP 3 trial randomized 611 adults to semaglutide 2.4 mg or placebo—both groups received 30 intensive behavioral therapy sessions and started with an 8-week low-calorie diet.
The semaglutide group lost 16.0% of body weight versus 5.7% with placebo (1).
That 10-percentage-point difference is the drug's contribution; the 5.7% is what lifestyle intervention alone achieved.
The medication amplifies behavioral change—it does not replace it.
What GLP-1 agonists actually do is reduce the neurobiological noise that makes sustained behavior change nearly impossible for many people.
GLP-1 receptor signaling dampens activation of brain appetitive circuits that drive food-seeking and reward in response to hedonic foods and environmental cues (2).
The drug quiets the signal; you still have to change what you put on your plate.
Myth 2: Taking GLP-1s Is "Cheating"
This myth rests on the assumption that obesity is a moral failure correctable by willpower alone. The neuroscience says otherwise.
Obesity involves dysregulated signaling in hypothalamic and mesolimbic circuits that govern hunger, satiety, and reward.
GLP-1 receptors are densely expressed in these brain regions precisely because glucagon-like peptide-1 is an endogenous hormone your body already uses to regulate energy intake (2).
Exogenous GLP-1 agonists restore what pathophysiology has broken.
We do not tell patients with hypertension that taking an antihypertensive is cheating.
We do not shame diabetics for using insulin.
Obesity is a chronic, relapsing disease with genetic, environmental, and neurobiological underpinnings.
Treating the biology is not a shortcut—it is medicine.
Myth 3: Side Effects Are Severe and Permanent
Gastrointestinal symptoms—nausea, vomiting, constipation, diarrhea are the most common adverse effects, and they are real.
A 2025 meta-analysis pooling 13 RCTs and nearly 27,000 participants found that overall GI adverse events were 1.86 times higher with semaglutide and tirzepatide compared to placebo (95% CI 1.56–2.21).
Tirzepatide carried a higher relative risk (RR 2.94; 95% CI 2.61–3.32) than semaglutide (RR 1.68; 95% CI 1.46–1.94).
Critically, neither agent significantly increased hepatic or pancreatic adverse events (3).
In the STEP 4 trial, 49.1% of participants continuing semaglutide reported GI events versus 26.1% on placebo, yet discontinuation rates due to adverse events were nearly identical—2.4% versus 2.2% (4).
The nausea typically peaks during dose titration and fades as the body adapts. Severe complications exist but are rare.
Myth 4: You'll Regain All the Weight When You Stop
The STEP 4 trial directly tested this. After a 20-week run-in during which all participants lost an average of 10.6% body weight on semaglutide, half were randomized to continue the drug and half switched to placebo.
Over the next 48 weeks, those continuing semaglutide lost an additional 7.9% body weight; those on placebo regained 6.9% (difference −14.8 percentage points; 95% CI −16.0 to −13.5; P<0.001)(4).
A 2025 systematic review and meta-analysis confirmed the pattern: discontinuing GLP-1 therapy leads to weight regain proportional to original loss—approximately 2.2 kg for liraglutide (95% CI 1.69–2.70) and 9.7 kg for semaglutide/tirzepatide (95% CI 5.78–13.60).
The authors concluded that GLP-1 therapy should be considered chronic treatment to prevent weight regain and associated adverse outcomes (5).
The expectation that you take a medication temporarily, cure the disease, and stop is the wrong framework.
Obesity requires ongoing management. This is not a failure of the drug; it is the nature of the disease.
Myth 5: GLP-1s Are Only for the Severely Obese
Why am I, a cardiologist, writing about GLP1?
Isnt it the job of people dealing with diabetes or obesity medicine?
The answer lies in the data from another large trial SELECT.
The SELECT trial enrolled 17,604 patients with established cardiovascular disease and a BMI of 27 or higher - many of whom were overweight rather than obese, and none had diabetes.
Semaglutide 2.4 mg weekly reduced the primary composite endpoint (cardiovascular death, nonfatal MI, or nonfatal stroke) by 20% (HR 0.80; 95% CI 0.72–0.90; P<0.001) over a mean follow-up of 39.8 months (6).
These were not patients seeking cosmetic weight loss.
They were secondary prevention cardiology patients, the same population we treat aggressively with statins and antihypertensives.
The FDA indication for semaglutide now includes cardiovascular risk reduction in adults with overweight or obesity and established CVD.
The bar is not morbid obesity—it is cardiometabolic risk.
Myth 6: GLP-1s Are Only for Weight Loss
This framing undersells the pharmacology.
A 2024 review catalogued effects of GLP-1 receptor agonists extending far beyond adiposity: improved glycemic control, reduced hepatic steatosis, improved lipid profiles, decreased systemic inflammation, and emerging signals for neuroprotection.
These drugs appear to increase lifespan even when controlling for weight loss (7).
The SELECT trial demonstrated cardiovascular event reduction independent of baseline diabetes status (6).
GLP-1 receptors are expressed in the heart, kidney, liver, and brain.
These drugs do not simply shrink fat cells—they modulate metabolism across organ systems.
Viewing them as "weight loss drugs" is like calling statins "cholesterol pills" while ignoring their pleiotropic effects on endothelial function and plaque stabilization.
The weight loss is visible; the systemic benefits are what matter for long-term outcomes.
The bottom line: GLP-1 agonists are serious medications for a serious disease.
They work best with lifestyle modification, require ongoing use for sustained benefit, and carry side effects that are usually manageable.
They are neither magic nor cheating—they are pharmacotherapy for a condition we finally have the tools to treat effectively.
References
1. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: The STEP 3 randomized clinical trial. JAMA. 2021 Apr 13;325(14):1403–13.
2. Grill HJ. A role for GLP-1 in treating hyperphagia and obesity. Endocrinology [Internet]. 2020 Aug 1;161(8). Available from: http://dx.doi.org/10.1210/endocr/bqaa093
3. Safwan M, Bourgleh MS, Alotaibi SA, Alotaibi E, Al-Ruqi A, El Raeya F. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta analysis. Ann Saudi Med. 2025 Mar;45(2):129–43.
4. Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA. 2021 Apr 13;325(14):1414–25.
5. Berg S, Stickle H, Rose SJ, Nemec EC. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obes Rev. 2025 Aug;26(8):e13929.
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023 Dec 14;389(24):2221–32.
7. Wilbon SS, Kolonin MG. GLP1 receptor agonists-effects beyond obesity and diabetes. Cells. 2023 Dec 28;13(1):65.